Skeptical Panel Probes Incyte Block on Sun’s Alopecia Drug (1)

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from launching its new alopecia drug, after suggesting the projected harm to Incyte Corp.'s patented but unapproved competing treatment was too speculative to justify the preliminary injunction.

Incyte alleged in a June 2024 complaint that Sun’s Leqselvi infringes US Patent No. 9,662,335, for deuterated versions of ruxolitinib, although Incyte’s rival product is still in early development and hasn’t begun clinical trials. A jury trial in the US District Court for the District of New Jersey is set for October 2026—just two months ...